Tivozanib third-line or fourth-line therapy improves PFS in metastatic renal cell carcinoma
02 Jan 2020
byDr Margaret Shi
Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.